Key result
Among 31 patients undergoing spinal cord stimulation for refractory angina, 96.7% were using anti-angina medications and 83.9% were on antiplatelet or anticoagulant agents at baseline.
Why the study?
To describe pre-operative characteristics and considerations for multidisciplinary evaluation in patients undergoing spinal cord stimulation for refractory angina pectoris.
Observational (n=31)
No
Patients undergoing spinal cord stimulation for refractory angina have significant cardiovascular comorbidities, highlighting the need for comprehensive multidisciplinary pre-operative evaluation.
Answers are grounded in this paper and cite their sources.
May support multidisciplinary pre-op evaluation in refractory angina; case series leaves open impact on outcomes.
Spinal cord stimulation (SCS) is used to treat a variety of chronic pain conditions refractory to more conservative management including refractory angina pectoris. We identified 31 patients who underwent SCS implantation for the indication of refractory angina at a single institution from 2003 through 2018. Sixteen patients were male, and 15 were female. Average age was 53.9 years. Prior to SCS implantation, all patients had at least one coronary angiogram. Ten (32.3%) patients had undergone percutaneous coronary intervention, and four (12.9%) had undergone coronary artery bypass grafting. Thirty patients (96.7%) were currently using anti-angina medications. Twenty-six patients (83.9%) were on antiplatelet or anticoagulant agents at the time of SCS evaluation. Spinal cord stimulation implanters must perform a comprehensive evaluation incorporating appropriate multidisciplinary care particularly in patients with refractory angina given their cardiovascular comorbidities. It is important to have baseline data (e.g., pain scores, nitroglycerin consumption, frequency of angina episodes, and a questionnaire, such as the Seattle Angina Questionnaire) to compare with follow-up data to help define treatment success. We report a single institution's pre-operative experience for patients undergoing SCS for refractory angina to illustrate unique pre-operative SCS considerations in this chronic pain population.
No takes yet. Share an insight, caveat, or question.
Langford et al. (2021) conducted an observational in Refractory angina pectoris (n=31). Spinal cord stimulation was evaluated. Among 31 patients undergoing spinal cord stimulation for refractory angina, 96.7% were using anti-angina medications and 83.9% were on antiplatelet or anticoagulant agents at baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: